Details relevant to the deaths of all patients registered with EBMT for autologous HSCT in SSc
| Sex | Age | Graft | Priming | Conditioning | Purge | Disease pattern | Organ involvement | Survival (D/Mt) | Cause of death |
|---|---|---|---|---|---|---|---|---|---|
| Italic type, procedure related deaths; normal type, disease related deaths; Bold type, patients who died after August 1999 not previously analysed in Binks paper.36 | |||||||||
| L, lung; GI, gastrointestinal; R, renal; O, other; PAH, pulmonary artery hypertension. | |||||||||
| F | 18.9 | ASCT | G-CSF | Cy+ATG | None | Diffuse | L | 11/0.36 | Diffuse alveolar haemorrhage |
| M | 47.2 | ASCT | Cy+G-CSF | Cy | NA | Diffuse | L, GI, R | 40/1.3 | CNS bleed |
| F | 48.1 | ASCT | Cy+G-CSF | Cy | None | Diffuse | L, O, GI | 30/1 | Septicaemia, heart failure |
| M | 42.9 | ASCT | Cy+G-CSF+VP16 | BEAM | CD34/T | Diffuse | O | 8/0.3 | Septicaemia, myocarditis |
| F | 58.5 | ASCT | Cy | Cy | None | Diffuse | L | 30/1 | Interstitial pneumonitis |
| F | 54.1 | ASCT | Cy+G-CSF | BCNU, thiotepa, fludarabine | CD34 | Diffuse | L, O, PAH | 217/7.2 | Pulmonary hypertension |
| F | 38.1 | ASCT | Cy+G-CSF | Cy | CD34+CAMPATH | Diffuse | L, O | 242/8 | Disease progression |
| F | 42.0 | ASCT | Cy+G-CSF | Cy | CD34+CAMPATH | Diffuse | A | 527/17.6 | VCS obstruction, disease progression |
| M | 39.6 | ASCT | Cy+G-CSF | Cy | CD34 | Diffuse | L, O | 193/6.4 | Disease progression |
| F | 51.0 | ABMT | Cy+G-CSF | Cy+ATG | None | Diffuse | O | 487/16.2 | Disease progression |
| F | 51.5 | ASCT | Cy+G-CSF | Cy | CD34 | Diffuse | L, O, PAH | 584/19.4 | Disease progression |
| F | 39.5 | ASCT | G-CSF | Cy+ATG | CD34 | NA | 578/19.2 | Disease progression | |
| F | 43.3 | ASCT | G-CSF | Cy+ATG | CD34 | Diffuse | L, O | 581/19.3 | Disease progression, interstitial pneumonitis |